Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

Innovent Biologics stock

1801.HK
KYG4818G1010
A2N7N8

Price

33.63
Today +/-
+0.09
Today %
+2.15 %

Innovent Biologics stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Innovent Biologics stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Innovent Biologics stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Innovent Biologics stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Innovent Biologics's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Innovent Biologics Stock Price History

DateInnovent Biologics Price
12/24/202433.63 undefined
12/23/202432.91 undefined
12/20/202433.03 undefined
12/19/202433.80 undefined
12/18/202434.22 undefined
12/17/202433.94 undefined
12/16/202433.96 undefined
12/13/202434.98 undefined
12/12/202435.62 undefined
12/11/202435.68 undefined
12/10/202435.58 undefined
12/9/202436.51 undefined
12/6/202435.33 undefined
12/5/202435.12 undefined
12/4/202435.04 undefined
12/3/202435.57 undefined
12/2/202436.12 undefined
11/29/202435.89 undefined
11/28/202436.44 undefined
11/27/202436.64 undefined

Innovent Biologics Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Innovent Biologics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Innovent Biologics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Innovent Biologics’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Innovent Biologics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Innovent Biologics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Innovent Biologics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Innovent Biologics’s growth potential.

Innovent Biologics Revenue, EBIT and net profit per share

DateInnovent Biologics RevenueInnovent Biologics EBITInnovent Biologics Net Income
2029e24.9 B undefined8.08 B undefined5.11 B undefined
2028e21.6 B undefined6.18 B undefined4.61 B undefined
2027e18.34 B undefined3.97 B undefined4.4 B undefined
2026e13.6 B undefined1.54 B undefined1.56 B undefined
2025e10.56 B undefined41.92 M undefined139.79 M undefined
2024e8.13 B undefined-1.08 B undefined-774.52 M undefined
20236.21 B undefined-1.47 B undefined-1.03 B undefined
20224.56 B undefined-3.02 B undefined-2.18 B undefined
20214.27 B undefined-2.66 B undefined-2.73 B undefined
20203.84 B undefined-426.5 M undefined-998.42 M undefined
20191.05 B undefined-1.78 B undefined-1.72 B undefined
20189.48 M undefined-1.5 B undefined-5.77 B undefined
201718.54 M undefined-624.73 M undefined-562.32 M undefined
20160 undefined-413.27 M undefined-504.2 M undefined

Innovent Biologics Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (B)NET INCOME (B)NET INCOME GROWTH (%)SHARES (B)DOCUMENTS
201620172018201920202021202220232024e2025e2026e2027e2028e2029e
00.020.011.053.844.274.566.218.1310.5613.618.3421.624.9
---50.0011,533.33267.0511.096.7236.2231.0529.8828.7034.8717.7815.29
-28,161.1156,322.2288.0689.9388.1779.5781.6862.3347.9937.2927.6523.4720.36
0000.923.463.763.635.07000000
-0.5-0.56-5.77-1.72-1-2.73-2.18-1.03-0.770.141.564.44.615.11
-11.51926.87-70.21-41.94173.35-20.12-52.87-24.63-117.961,020.14182.724.6310.86
0.880.880.331.181.361.461.491.56000000
--------------
Details

Keystats

ⓘ

Revenue and Growth

The Innovent Biologics Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Innovent Biologics is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (B)RECEIVABLES (B)OTHER REC. (M)INVENTORIES (B)OTHER CURRENT LIAB. (B)CURRENT ASSETS (B)TANGIBLE ASSETS (B)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (B)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (B)TOTAL ASSETS (B)LIABILITIESCOMMON STOCK (k)ADDITIONAL PAID-IN CAPITAL (B)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (B)LIABILITIES (M)PROVISIONS (B)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (B)SHORT-TERM REC. (B)LONG-T. LIAB. (B)DEFERRED TAXES (M)OTHER LIAB. (B)LONG-T. LIABILITIES (B)DEBT (B)TOTAL CAPITAL (B)
20162017201820192020202120222023
               
1.81.324.534.78.057.958.2610.12
000.010.250.480.970.581.01
13.8713.0713.7300000
0.040.060.070.360.711.351.430.97
0.030.060.070.150.241.291.241.33
1.871.454.695.469.4711.5511.5113.43
0.790.821.121.522.183.384.064.85
0001.9812.94417.26630.2794.09
100.88135.53250.31251.97139.27127.66193.060
00000.030.771.21.27
00000000
55.3454.0952.840000283.12
0.951.011.431.782.374.696.087.2
2.822.466.117.2311.8316.2417.5920.63
               
68798797101105112
0.010.0511.7513.8918.5422.4924.7127.32
-1,394.87-1,996.76-7,556.91-9,129.22-9,761.58-12,045.35-13,836.46-14,671.76
000002-18.45-20.11
00000-120.01-120.89-105.15
-1.38-1.944.194.768.7810.3310.7312.53
21.234.8442.8284.28120.62195.05325.62372.55
0.030.110.530.780.821.681.522.16
2416.9584.38142.51274.13790.15741.92728.33
00000000
00.010.010.030.270.390.911.22
0.080.160.671.041.493.053.54.48
0.50.510.780.830.942.112.312.4
00000000
3.23.410.470.60.630.751.051.22
3.73.921.251.431.572.863.363.62
3.774.081.922.473.065.916.868.1
2.392.146.117.2311.8316.2417.5920.63
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Innovent Biologics provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Innovent Biologics's financial health and stability.

Assets

Innovent Biologics's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Innovent Biologics must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Innovent Biologics after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Innovent Biologics's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (B)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (B)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (B)NET CHANGE IN EQUITY (B)CASH FLOW FROM FINANCING ACTIVITIES (B)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (B)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
2016201720182019202020212022
-544-716-5,872-1,719-858-3,051-2,170
5359628685204319
0000000
-1143417-127-473-116243
0.140.124.380.10.940.94-0.31
262432414578104
000-131392666
-362-492-1,011-1,664-307-2,024-1,918
-58-90-312-365-521-1,847-1,365
-572-349855-2,569-5,184-2,698-1,435
-0.51-0.261.17-2.2-4.66-0.85-0.07
0000000
00.010.280.020.341.180.69
1.670.14.322.174.663.952.13
1.640.094.432.114.9152.89
-26-24-167-89-88-13173
0000000
0.73-0.784.34-2.1-1.150.08-0.34
-421.44-583.24-1,324.57-2,030.35-829.34-3,872.36-3,284.3
0000000

Innovent Biologics stock margins

The Innovent Biologics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Innovent Biologics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Innovent Biologics.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Innovent Biologics's sales revenue. A higher gross margin percentage indicates that the Innovent Biologics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Innovent Biologics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Innovent Biologics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Innovent Biologics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Innovent Biologics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Innovent Biologics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Innovent Biologics Margin History

Innovent Biologics Gross marginInnovent Biologics Profit marginInnovent Biologics EBIT marginInnovent Biologics Profit margin
2029e81.69 %32.47 %20.51 %
2028e81.69 %28.6 %21.33 %
2027e81.69 %21.66 %24.01 %
2026e81.69 %11.35 %11.46 %
2025e81.69 %0.4 %1.32 %
2024e81.69 %-13.28 %-9.52 %
202381.69 %-23.75 %-16.56 %
202279.57 %-66.18 %-47.83 %
202188.16 %-62.22 %-63.91 %
202089.91 %-11.1 %-25.97 %
201988.08 %-169.76 %-164.19 %
201881.69 %-15,779.4 %-60,899.99 %
201781.69 %-3,369.99 %-3,033.33 %
201681.69 %0 %0 %

Innovent Biologics Stock Sales Revenue, EBIT, Earnings per Share

The Innovent Biologics earnings per share therefore indicates how much revenue Innovent Biologics has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Innovent Biologics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Innovent Biologics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Innovent Biologics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Innovent Biologics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Innovent Biologics Revenue, EBIT and net profit per share

DateInnovent Biologics Sales per ShareInnovent Biologics EBIT per shareInnovent Biologics Earnings per Share
2029e15.2 undefined0 undefined3.12 undefined
2028e13.18 undefined0 undefined2.81 undefined
2027e11.19 undefined0 undefined2.69 undefined
2026e8.3 undefined0 undefined0.95 undefined
2025e6.45 undefined0 undefined0.09 undefined
2024e4.97 undefined0 undefined-0.47 undefined
20233.98 undefined-0.95 undefined-0.66 undefined
20223.06 undefined-2.02 undefined-1.46 undefined
20212.93 undefined-1.83 undefined-1.87 undefined
20202.83 undefined-0.31 undefined-0.74 undefined
20190.89 undefined-1.51 undefined-1.46 undefined
20180.03 undefined-4.47 undefined-17.24 undefined
20170.02 undefined-0.71 undefined-0.64 undefined
20160 undefined-0.47 undefined-0.57 undefined

Innovent Biologics business model

Innovent Biologics Inc. is an innovative biopharmaceutical company that focuses on the discovery, development, and commercialization of world-leading biological therapies. The company was founded in 2011 by a group of outstanding scientists who already had extensive experience in biological research and development. Since then, Innovent Biologics Inc. has achieved many successes and has become a significant player in the biopharmaceutical industry. Innovent Biologics' business model is based on the use of cutting-edge technology and collaboration with partners to develop and bring innovative biopharmaceuticals to the market. The company utilizes a platform technology based on a combination of protein production and antibody development to provide a strong foundation for its innovative pipeline of therapeutics. Innovent Biologics specializes in three main areas: cancer therapy, autoimmune diseases, and ophthalmology. The company has developed an impressive number of product candidates to meet the need for innovative therapeutics in these areas. In the field of cancer therapy, Innovent Biologics specializes particularly in the treatment of lung tumors. The company has successfully developed tyrosine kinase inhibitors targeting important therapy targets. Additionally, the company has also developed antibodies against cancer that stimulate the patient's immune system to fight tumor cells. Innovent Biologics is also a leader in the development of drugs for the treatment of autoimmune diseases such as rheumatoid arthritis and psoriasis. By identifying highly specific antibodies with therapeutic potential, the company has developed a pipeline of promising drug candidates. In the field of ophthalmology, Innovent Biologics has achieved remarkable successes. The company has developed an innovative therapeutic antibody platform specifically targeting the treatment of eye diseases. This platform allows for the optimization of the drug to better suit the eye and achieve higher efficacy. Innovent Biologics has already discovered several antibody candidates that have produced promising clinical results. In addition to its product candidates, Innovent Biologics has also formed partnerships with other industry players. The company collaborates closely with other biopharmaceutical companies to jointly develop and market innovative therapeutics. Overall, Innovent Biologics Inc. has built an impressive track record and experience in a relatively short period. It is a leading player in the development of biopharmaceuticals that have the potential to revolutionize the healthcare industry. The company has a strong pipeline of product candidates in various therapy areas, supported by innovative platform technology. Innovent Biologics is able to further expand its work through close collaboration with partners and a variety of collaborators. Innovent Biologics is one of the most popular companies on Eulerpool.com.

Innovent Biologics SWOT Analysis

Strengths

1. Strong Research and Development Capabilities: Innovent Biologics Inc has a solid R&D team that is capable of developing innovative and high-quality biologic drugs.

2. Strategic Partnerships: The company has established strategic partnerships with leading pharmaceutical companies, which provide access to resources and expertise, enhancing its competitive advantage.

3. Robust Product Pipeline: Innovent Biologics Inc has a diverse and promising pipeline of biologic drugs, which ensures future growth opportunities and potential revenue streams.

Weaknesses

1. Dependency on Partnerships: While partnerships are a strength, heavy reliance on them can also be a weakness, as the success and timing of collaborative projects may be beyond the company's control.

2. Limited Market Presence: Innovent Biologics Inc is relatively new in the biopharmaceutical industry, which limits its brand recognition and market penetration compared to established competitors.

3. Regulatory Challenges: The company needs to navigate complex regulatory processes for drug approvals, which can be time-consuming and costly, potentially delaying market entry.

Opportunities

1. Growing Biopharmaceutical Market: The increasing demand for biologic drugs presents a significant opportunity for Innovent Biologics Inc to capture a larger market share and generate higher revenues.

2. Expansion into International Markets: The company can explore expansion opportunities in untapped international markets, leveraging its expertise and partnerships to enter new regions.

3. Strategic Collaborations: Innovent Biologics Inc can seek further collaborations with academic institutions, research organizations, and industry players to enhance technology, knowledge sharing, and product development.

Threats

1. Intense Competition: The biopharmaceutical industry is highly competitive, with many established players and emerging companies. Innovent Biologics Inc faces the risk of increased competition, which may impact its market share and pricing power.

2. Intellectual Property Risks: Protecting intellectual property is crucial for biopharmaceutical companies. Innovent Biologics Inc faces the threat of patent infringement lawsuits or unauthorized use of its proprietary technologies, potentially harming its business.

3. Regulatory and Compliance Risks: Changes in regulatory requirements or non-compliance with existing regulations can pose challenges for drug development and commercialization, leading to delays or restrictions on product offerings.

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Innovent Biologics Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Innovent Biologics historical P/E ratio, EBIT multiple, and P/S ratio

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Innovent Biologics shares outstanding

The number of shares was Innovent Biologics in 2023 — This indicates how many shares 1.56 B is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Innovent Biologics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Innovent Biologics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Innovent Biologics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Innovent Biologics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for Innovent Biologics.

Innovent Biologics latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/2024-0.26 -0.1  (61.18 %)2024 Q2
12/31/2023-0.51 -0.21  (59.61 %)2023 Q4
6/30/2023-0.73 -0.12  (83.12 %)2023 Q2
12/31/2022-1.58 -0.91  (42.44 %)2022 Q4
6/30/2022-1.04 -0.74  (28.87 %)2022 Q2
12/31/2021-0.93 -1.08  (-16.35 %)2021 Q4
6/30/2021-0.24 -0.47  (-91.99 %)2021 Q2
12/31/20200.4 -0.28  (-170.39 %)2020 Q4
6/30/2020-0.31 -0.46  (-50.33 %)2020 Q2
12/31/2019-0.39 -0.84  (-116.72 %)2019 Q4
1
2

Eulerpool ESG Scorecard© for the Innovent Biologics stock

Eulerpool World ESG Rating (EESG©)

64/ 100

🌱 Environment

92

👫 Social

66

🏛️ Governance

33

Environment

Scope 1 - Direct Emissions
66.74
Scope 2 - Indirect emissions from purchased energy
22,236.21
Scope 3 - Indirect emissions within the value chain
Total CO₂ emissions
22,302.95
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency

Social

Percentage of female employees50.132
Percentage of women in management
Percentage of Asian employees
Share of Asian management
Percentage of Hispanic/Latino employees
Hispano/Latino Management share
Percentage of Black employees
Black Management Share
Percentage of white employees
White Management Share
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic

Governance (Corporate Governance)

Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Innovent Biologics shareholders

%
Name
Stocks
Change
Date
7.92689 % Temasek Holdings Pte. Ltd.129,840,850-15,0008/19/2024
6.55536 % Yu (De-Chao Michael)107,375,525-1,750,00010/2/2024
5.12171 % Capital Research Global Investors83,892,654-925,3187/10/2024
2.83466 % The Vanguard Group, Inc.46,431,11230,5009/30/2024
2.22469 % GF Fund Management Co., Ltd.36,440,000-7,793,6556/30/2024
1.98217 % Norges Bank Investment Management (NBIM)32,467,47617,497,1316/30/2024
1.54282 % BlackRock Institutional Trust Company, N.A.25,271,075244,0009/30/2024
1.50606 % Bosera Asset Management Co., Ltd.24,669,000114,5006/30/2024
1.45115 % Harvest Fund Management Co., Ltd.23,769,500-2,595,0006/30/2024
1.37262 % Capital International, Inc.22,483,217513,5007/10/2024
1
2
3
4
5
...
10

Innovent Biologics Executives and Management Board

Dr. De-Chao Yu

(59)
Innovent Biologics Executive Chairman of the Board, Chief Executive Officer (since 2011)
Compensation 32.96 M

Mr. Hao Xi Ede

(64)
Innovent Biologics Executive Director (since 2018)
Compensation 6.96 M

Dr. Kaixian Chen

(78)
Innovent Biologics Non-Executive Independent Director
Compensation 400,000

Dr. Charles Cooney

(78)
Innovent Biologics Non-Executive Independent Director
Compensation 400,000

Ms. I-Yin Hsu

(48)
Innovent Biologics Non-Executive Independent Director
Compensation 400,000
1
2

Innovent Biologics Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
HUTCHMED (China) Stock
HUTCHMED (China)
SupplierCustomer0,840,940,930,76
HBM Holdings Stock
HBM Holdings
SupplierCustomer0,54-0,340,670,900,89
Roche Holding Stock
Roche Holding
SupplierCustomer0,340,80-0,460,17-0,29-0,32
Shenzhen Chipscreen Biosciences A Stock
Shenzhen Chipscreen Biosciences A
SupplierCustomer0,290,740,850,860,890,06
Shanghai Medicilon A Stock
Shanghai Medicilon A
SupplierCustomer0,260,65-0,370,900,500,15
Alector Stock
Alector
SupplierCustomer0,130,810,710,860,770,42
Coherus BioSciences Stock
Coherus BioSciences
SupplierCustomer-0,280,770,380,920,510,24
Eli Lilly Stock
Eli Lilly
SupplierCustomer-0,340,67-0,72-0,40-0,64-0,16
Sana Biotechnology Stock
Sana Biotechnology
SupplierCustomer-0,400,40-0,520,930,86
Incyte Stock
Incyte
SupplierCustomer-0,550,56-0,64-0,660,12
1

Most common questions regarding Innovent Biologics

What values and corporate philosophy does Innovent Biologics represent?

Innovent Biologics Inc is committed to transforming the lives of patients through innovative biopharmaceuticals. The company values integrity, excellence, and patient-centricity. Innovent Biologics believes in creating a patient-oriented ecosystem by focusing on extensive research and development efforts, robust clinical trials, and rigorous quality control processes. The company's corporate philosophy centers around leveraging cutting-edge technology, collaborating with global partners, and delivering high-quality and affordable biologics to improve healthcare access worldwide. Innovent Biologics Inc's unwavering dedication to scientific advancement and patient welfare drives its mission to revolutionize the treatment landscape and provide hope for patients in need.

In which countries and regions is Innovent Biologics primarily present?

Innovent Biologics Inc is primarily present in China.

What significant milestones has the company Innovent Biologics achieved?

Innovent Biologics Inc has achieved significant milestones in its journey. The company has successfully developed and launched several innovative biologics, including multiple oncology and autoimmune disease therapies. Innovent has secured numerous partnerships and collaborations with leading pharmaceutical companies, expanding its global reach and enhancing its product pipeline. Furthermore, the company has received several regulatory approvals, enabling it to bring life-saving treatments to patients around the world. Innovent's commitment to research and development, along with its dedication to improving patient outcomes, has positioned it as a key player in the biopharmaceutical industry.

What is the history and background of the company Innovent Biologics?

Innovent Biologics Inc. is a leading biopharmaceutical company specializing in the development and commercialization of innovative biological drugs. Founded in 2011, the company is headquartered in Suzhou, China and has a global presence. Innovent Biologics is committed to addressing unmet medical needs and improving patient outcomes through its extensive pipeline of monoclonal antibodies and other biologics. A key focus of the company is the development of biosimilars, which are highly similar versions of existing biologics with demonstrated equivalence in terms of safety, efficacy, and quality. Innovent Biologics has established strategic partnerships with numerous international pharmaceutical companies, strengthening its position in the global market.

Who are the main competitors of Innovent Biologics in the market?

The main competitors of Innovent Biologics Inc in the market include established biopharmaceutical companies such as AstraZeneca, Eli Lilly and Company, Novartis International AG, and Roche Holding AG. These companies also focus on the development of innovative biologics and have a significant presence in the global biopharmaceutical industry. However, Innovent Biologics Inc differentiates itself through its unique product pipeline and strategic collaborations, aiming to offer novel and affordable biologic medicines to patients globally.

In which industries is Innovent Biologics primarily active?

Innovent Biologics Inc is primarily active in the biotechnology and pharmaceutical industries.

What is the business model of Innovent Biologics?

Innovent Biologics Inc. is a biopharmaceutical company specializing in the discovery, development, and commercialization of innovative antibody-based drugs. With a focus on the Chinese market, Innovent combines advanced technology platforms, a robust pipeline, and strategic collaborations to address unmet medical needs. The company utilizes its expertise in areas such as cancer, autoimmune, and metabolic diseases to develop novel therapies that offer improved efficacy, safety, and affordability. Innovent's business model revolves around utilizing its research and development capabilities, partnerships, and market insights to bring life-changing biologics to patients in China and beyond.

What is the P/E ratio of Innovent Biologics 2024?

The Innovent Biologics P/E ratio is -67.71.

What is the P/S ratio of Innovent Biologics 2024?

The Innovent Biologics P/S ratio is 6.45.

What is the Quality Investing of Innovent Biologics?

The Quality Investing for Innovent Biologics is 3/10.

What is the revenue of Innovent Biologics 2024?

The expected Innovent Biologics revenue is 8.13 B CNY.

How high is the profit of Innovent Biologics 2024?

The expected Innovent Biologics profit is -774.52 M CNY.

What is the business model of Innovent Biologics

Innovent Biologics Inc is a leading biotechnology company in China specializing in the development and manufacturing of innovative biologic cancer therapies. The company was founded in 2011 and has since experienced significant growth. Innovent Biologics Inc offers a wide range of products and services, including the development of new biologics, production and manufacturing of biologics, as well as the marketing and sales of biologics. Innovent has an extensive pipeline of cancer therapies that are approved or in clinical trials both in China and globally. The flagship product of Innovent is Sintilimab, an innovative cancer immunotherapy. It has approval in China for non-small cell lung cancer (NSCLC) and Hodgkin lymphoma (HL), and was approved in China in November 2018. It is the first product developed and approved by a Chinese biopharma company in China, marking a turning point for innovative drug development in China. Sintilimab has also received limited market approval in other countries such as the USA, Europe, and Japan. Another important product in Innovent's pipeline is IBI308, a CTLA-4 antibody being developed in combination with Sintilimab for the treatment of solid tumors. Other key product candidates from Innovent include IBI303 (a HER2 antibody), IBI305 (a CD47 antibody), IBI202 (an EGFR TKI), and IBI101 (an antibody targeting severe eye diseases such as AMD and DME). Innovent also has its own biologics manufacturing capacity to meet the demand for various cancer therapies at a global level. It has a production facility in Suzhou built according to cGMP guidelines and equipped with state-of-the-art equipment and technology. Through the use of advanced technologies and scientific innovations, Innovent aims to achieve faster market approval for their products and enhance competitiveness in the global market. In addition to the development and manufacturing of biologics, Innovent is also engaged in collaborations and partnerships. It has formed partnerships with some of the world's leading biopharma and pharmaceutical companies to further improve and expand its innovative technologies and products. Overall, the business model of Innovent Biologics Inc has revolutionized the cancer market in China and internationally. With a strong focus on research and development, production and marketing strategies, as well as collaborations and partnerships, the company has made a sustainable impact on global cancer treatment. Innovent will continue to explore and develop innovative therapies to meet the challenges of cancer treatment.

What is the Innovent Biologics dividend?

Innovent Biologics pays a dividend of 0 CNY distributed over payouts per year.

How often does Innovent Biologics pay dividends?

The dividend cannot currently be calculated for Innovent Biologics or the company does not pay out a dividend.

What is the Innovent Biologics ISIN?

The ISIN of Innovent Biologics is KYG4818G1010.

What is the Innovent Biologics WKN?

The WKN of Innovent Biologics is A2N7N8.

What is the Innovent Biologics ticker?

The ticker of Innovent Biologics is 1801.HK.

How much dividend does Innovent Biologics pay?

Over the past 12 months, Innovent Biologics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Innovent Biologics is expected to pay a dividend of 0 CNY.

What is the dividend yield of Innovent Biologics?

The current dividend yield of Innovent Biologics is .

When does Innovent Biologics pay dividends?

Innovent Biologics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Innovent Biologics?

Innovent Biologics paid dividends every year for the past 0 years.

What is the dividend of Innovent Biologics?

For the upcoming 12 months, dividends amounting to 0 CNY are expected. This corresponds to a dividend yield of 0 %.

In which sector is Innovent Biologics located?

Innovent Biologics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Innovent Biologics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Innovent Biologics from 12/26/2024 amounting to 0 CNY, you needed to have the stock in your portfolio before the ex-date on 12/26/2024.

When did Innovent Biologics pay the last dividend?

The last dividend was paid out on 12/26/2024.

What was the dividend of Innovent Biologics in the year 2023?

In the year 2023, Innovent Biologics distributed 0 CNY as dividends.

In which currency does Innovent Biologics pay out the dividend?

The dividends of Innovent Biologics are distributed in CNY.

All fundamentals about Innovent Biologics

Our stock analysis for Innovent Biologics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Innovent Biologics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.